← Retour au Screener

Sector: Santé
Open in Terminal → OCULLive chart · Key metrics · News · Smart money

Ocular Therapeutix

OCUL Mid Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

8,22 €
-2.18% aujourd'hui
52W: 5,43 € – 14,33 €
52W Low: 5,43 € Position: 31.3% 52W High: 14,33 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
39.68x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,8 Md €
Capitalisation boursière
Croissance du CA
0.8%
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-68.55%
Rentabilité des capitaux propres
Beta
0.9
Sensibilité au marché
Positions vendeuses
13.53%
% du flottant vendu à découvert
Volume moyen
3,067,619
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
11 analysts
Avg. Price Target
22,67 €
+175.72% upside
Target Range
15,69 € – 29,64 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 325 Exchange: NGM

Ocular Therapeutix en bref

Ocular Therapeutix (OCUL) is currently trading at 8,22 € with a market capitalization of 1,8 Md €. The 52-week range spans from 5,43 € to 14,33 €; the current price is 42.6% below the yearly high. Year-over-year revenue growth stands at +0.8%.

💰 Dividende

Ocular Therapeutix currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Ocular Therapeutix (OCUL) au consensus : Achat Fort. L'objectif de cours moyen est de 22,67 €, soit un potentiel de +175.72% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,69 € à 29,64 €.

Ocular Therapeutix : la thèse d'investissement en détail

Ocular Therapeutix (OCUL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 175.72% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 0.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 13.53% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 175.72% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 13.66)
Points faibles
  • Positions vendeuses élevées (13.53%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
7,85 €
+4.78% vs. cours
MM 200 jours
9,18 €
-10.45% vs. cours
Sous le plus haut 52s
−42.6%
14,33 €
Au-dessus du plus bas 52s
+51.4%
5,43 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
0.9 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
13.53% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
13.66 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (13.53%).

Trading Data

50-Day MA: 7,85 €
200-Day MA: 9,18 €
Volume: 6,014,188
Avg. Volume: 3,067,619
Short Ratio: 8.74
P/B Ratio: 3.55x
Debt/Equity: 13.66x
Free Cash Flow: -129 684 924 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Ocular Therapeutix?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut